Cargando…

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study

We evaluated relative vaccine effectiveness (rVE) of 4- vs. 3-dose mRNA-1273 against SARS-CoV-2 infection, and COVID-19 hospitalization and death in immunocompetent adults aged ≥50 years at Kaiser Permanente Southern California. We included 178,492 individuals who received a fourth dose of mRNA-1273...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ku, Jennifer H., Sy, Lina S., Qian, Lei, Ackerson, Bradley K., Luo, Yi, Tubert, Julia E., Lee, Gina S., Florea, Ana, Bruxvoort, Katia J., Xie, Fagen, Qiu, Sijia, Chavers, Scott, Talarico, Carla A., Tseng, Hung Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2023
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239903/ https://www.ncbi.nlm.nih.gov/pubmed/37301708 http://dx.doi.org/10.1016/j.vaccine.2023.06.016

Ejemplares similares

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
por: Florea, Ana, et al.
Publicado: (2022)

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
por: Bruxvoort, Katia J., et al.
Publicado: (2021)

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

784. Real-world effectiveness of the mRNA-12733-dose primary series against COVID-19 in an immunocompromised population Interim results from a prospective observational cohort study
por: Ku, Jennifer H, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
por: Malden, Deborah E., et al.
Publicado: (2021)

Differences in Estimates of Post-Herpetic Neuralgia Between Medical Chart Review and Self-Report
por: Tanenbaum, Hilary C, et al.
Publicado: (2020)

Fourth Interim Report
por: Y. Blumenfeld and John Cornell
Publicado: (26/1)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
por: Mues, Katherine E., et al.
Publicado: (2022)

115. Post-licensure Safety Study of New-onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis in Adult Recipients of HepB-CPG Vaccine Versus HepB-alum Vaccine
por: Ackerson, Bradley, et al.
Publicado: (2022)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Challenges in Phase 4 post-licensure safety studies using real world data in the United States: Hepatitis B vaccine example
por: Bruxvoort, Katia, et al.
Publicado: (2021)

917. Development and Validation of an Automated Natural Language Processing Method for Identifying Postherpetic Neuralgia from Electronic Health Records
por: Zheng, Chengyi, et al.
Publicado: (2023)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US
por: Hung Nguyen, Van, et al.
Publicado: (2023)

Text-Based Identification of Herpes Zoster Ophthalmicus With Ocular Involvement in the Electronic Health Record: A Population-Based Study
por: Zheng, Chengyi, et al.
Publicado: (2021)

Association of Number of Doses With Hepatitis B Vaccine Series Completion in US Adults
por: Bruxvoort, Katia, et al.
Publicado: (2020)

mRNA-1273: Myocarditis: case report
Publicado: (2021)

mrna-1273: Erythema nodosum: case report
Publicado: (2021)

mrna-1273: Immediate hypersensitivity: case report
Publicado: (2021)

mrna-1273: Acute myocarditis: case report
Publicado: (2021)

mRNA-1273: Myopericarditis: case report
Publicado: (2021)

mRNA 1273: Anaphylaxis: case report
Publicado: (2021)

mrna-1273: Haematuria: 2 case reports
Publicado: (2021)

A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report
por: Masuda, Taisei, et al.
Publicado: (2022)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

286. Hepatitis B Vaccine Compliance: Comparing 2-Dose and 3-Dose Vaccines
por: Bruxvoort, Katia, et al.
Publicado: (2019)

mRNA-1273: Various toxicities: case report
Publicado: (2021)

mrna-1273/tozinameran: Myocarditis: 8 case reports
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_01rlogo0lcvaujuthted186roh